4-hydroxy-3-methoxy-N-methyl-benzamide | 60515-31-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxy-3-methoxy-N-methyl-benzamide
• 英文别名: 4-hydroxy-3-methoxy-N-methylbenzamide
• CAS: 60515-31-3
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: RKXKSZGILNYOAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  333.2±32.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3-methoxy-N-methyl-benzamide 在 1,2-bis(dicyclohexylphosphonium)ethane bis(tetrafluoroborate) 、 palladium diacetate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0~100.0 ℃ 、515.03 kPa 条件下， 反应 18.0h， 生成 N¹-(tert-Butyl)-2-methoxy-N⁴-methylterephthalamide
  参考文献：
  名称：

  Aminocarbonylation of Aryl Tosylates to Carboxamides

  摘要：

  The palladium - catalyzed aminocarbonylation of aryl tosylates with amines is reported. Suitable conditions were identified by high throughput reaction screening and then further optimized. The substrate scope of the reaction with respect to the aryl tosylate component and the amine component are reported. Competitive aminolysis of the aryl tosylates to afford the amine toluenesulfonamides and the phenol was not observed.

  DOI：

  10.1021/acs.orglett.5b01283
• 作为产物：
  描述：

  4-hydroxy-3-methoxy-N-methyl-benzamide N-methylammonium salt 以 乙酸乙酯 为溶剂， 反应 2.0h， 生成 4-hydroxy-3-methoxy-N-methyl-benzamide
  参考文献：
  名称：

  Piperazine derivatives

  摘要：

  这项发明涉及一种具有化学式(I)的化合物 或其药用可接受的盐、溶剂合物或衍生物，其中R 1 至R 5 在描述中有定义，并涉及其制备方法、制备中使用的中间体、含有它们的组合物以及这些衍生物的用途。 本发明的化合物抑制gp120与CD4的相互作用，因此在治疗HIV、与HIV有遗传关系的逆转录病毒感染或艾滋病方面有用。

  公开号：

  US20050043300A1

文献信息

• Piperazine derivatives
  申请人：Middleton Stuart Donald

  公开号：US20050043300A1

  公开（公告）日：2005-02-24

  This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R 1 to R 5 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives. The compounds of the present invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, or AIDS.

  这项发明涉及一种具有化学式(I)的化合物 或其药用可接受的盐、溶剂合物或衍生物，其中R 1 至R 5 在描述中有定义，并涉及其制备方法、制备中使用的中间体、含有它们的组合物以及这些衍生物的用途。 本发明的化合物抑制gp120与CD4的相互作用，因此在治疗HIV、与HIV有遗传关系的逆转录病毒感染或艾滋病方面有用。
• Total synthesis of aristolactam alkaloids via synergistic C–H bond activation and dehydro-Diels–Alder reactions
  作者：Mallu Chenna Reddy、Masilamani Jeganmohan

  DOI：10.1039/c7sc00161d

  日期：——

  concise total synthesis of aristolactam alkaloids by a synergistic combination of C–H bond activation and dehydro-Diels–Alder reactions is described. To achieve the synthesis two new synthetic methodologies, namely the oxidative cyclization of benzamides with vinyl sulfone leading to 3-methyleneisoindolin-1-ones via a ruthenium-catalyzed C–H bond activation, and a dehydro-Diels–Alder reaction followed by

  描述了通过 C-H 键活化和脱氢-Diels-Alder 反应的协同组合来简明地全合成马兜铃内酰胺生物碱。为了实现合成，采用了两种新的合成方法，即苯甲酰胺与乙烯基砜的氧化环化，通过钌催化的 C-H 键活化生成 3-亚甲基异吲哚啉-1-酮，以及脱氢-狄尔斯-阿尔德反应，然后生成氟化物开发了 3-亚甲基异吲哚啉-1-酮与苯炔的离子介导脱磺酰化。所提出的方法允许从容易获得的起始材料构建所有马兜铃内酰胺环。
• [EN] PBD ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTÉRIENS DE TYPE PBD
  申请人：KING'S COLLEGE LONDON

  公开号：WO2017098257A1

  公开（公告）日：2017-06-15

  The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections. The PBDs are compounds of formula (I): and salts and solvates thereof; wherein: dotted lines indicates the optional presence of a double bond; X, X1, X2, X3 and X4 are connecting functional groups; L is C1-12 alkylene; R4, R5 and R6 are independently selected from phenylene, cyclopentanylene, cyclohexanylene, 5 - to 9 -membered heteroarylene and 5 - to 6-membered hetereocyclylene groups, and these groups are optionally substituted with up to three optional substituent groups; R7 is selected from N(C1-6 alkyl)(C1-6alkyl), 5 - to 6-membered nitrogen-containing hetereocyclyl groups, a monosaccharide moiety and an amino monosaccharide moiety wherein these groups are optionally substituted; and R8 and R9 either together form a double bond, or are selected from H and OR14, or R8 is a prodrug moiety and R9 is OR14; m is 0 or 1; with the proviso that when X4 is C(O)NH then the up to three optional substituents of R7 are not selected from (CH2)k -CO2R12; with the proviso that when X4 is (CH2)tO then R4 is not phenylene, m is 1 and R6 is not a 5 - to 9 -membered heteroarylene; and with the proviso that when X4 is C(O)NH or NHC(O) that R4 and/or R6 is not 5 - to 9 -membered heteroarylene.

  该发明涉及吡咯苯二氮杂环烷化合物（PBD）及其药用可接受盐，其作为药物具有治疗细菌感染的功效。PBD是具有以下结构式（I）的化合物：及其盐和溶剂化物；其中：虚线表示双键的可选存在；X、X1、X2、X3和X4是连接的功能基团；L为C1-12烷基；R4、R5和R6分别选自苯环、环戊烷基、环己烷基、5-至9-成员杂芳烃基和5-至6-成员杂环烷基，这些基团可选地被高达三个可选取代基团取代；R7选自N（C1-6烷基）（C1-6烷基）、5-至6-成员含氮杂环基团、单糖基团和氨基单糖基团，其中这些基团可选地被取代；R8和R9要么一起形成双键，要么选自H和OR14，或者R8是前药基团且R9是OR14；m为0或1；但是当X4为C（O）NH时，R7的高达三个可选取代基团不选自（CH2）k-CO2R12；但是当X4为（CH2）tO时，R4不是苯环，m为1且R6不是5-至9-成员杂芳烃基；但是当X4为C（O）NH或NHC（O）时，R4和/或R6不是5-至9-成员杂芳烃基。
• Peg-based adhesive phenylic derivatives and methods of synthesis and use
  申请人：MURPHY John L.

  公开号：US20160032047A1

  公开（公告）日：2016-02-04

  The invention provides compositions that use phenylic derivatives to provide adhesive properties. Selection of phenylic derivatives with linkers or linking groups, and the linkages between the linkers or linking groups with polyalkylene oxides, provided herein may be configured to control curing time, biodegradation and/or swelling.

  本发明提供了使用苯基衍生物作为黏合剂的组合物。本发明提供了苯基衍生物与连接剂或连接基团的选择，以及连接剂或连接基团与聚烷氧化物之间的连接，可以配置以控制固化时间、生物降解和/或肿胀。
• Discovery of a small molecule inhibitor through interference with the gp120–CD4 interaction
  作者：David H. Williams、Fiona Adam、David R. Fenwick、Juin Fok-Seang、Iain Gardner、Duncan Hay、Rawal Jaiessh、Donald S. Middleton、Charles E. Mowbray、Tanya Parkinson、Manos Perros、Christopher Pickford、Michelle Platts、Amy Randall、Daniel Siddle、Peter T. Stephenson、Thien-Duc Tran、Hannah Vuong

  DOI：10.1016/j.bmcl.2009.06.080

  日期：2009.9

  A series of piperazine derivatives were designed and synthesised as gp120-CD4 inhibitors. SAR studies led to the discovery of potent inhibitors in a cell based anti viral assay represented by compounds 9 and 28. The rat pharmacokinetic and antiviral profiles of selected compounds are also presented. Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.